Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174122 | 0.89 | POLB (0.52) | ALDH1A1KDM4EHRH3LMNAEPHX2 | |
| SCHEMBL12937241 | 0.87 | HRH3 (0.60) | KDM4EHRH3EPHX2 | |
| SCHEMBL12804795 | 0.87 | CD274 (0.48) | ALDH1A1KDM4EHRH3GAASMN1; SMN2 | |
| SCHEMBL10174120 | 0.86 | HRH3 (0.48) | HRH3LMNAEPHX2 | |
| SCHEMBL30911745 | 0.86 | HRH3 (0.66) | ALDH1A1KDM4EHRH3SMN1; SMN2HIF1A | |
| SCHEMBL10174121 | 0.85 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAGAASMN1; SMN2 | |
| SCHEMBL10174117 | 0.83 | HRH3 (0.46) | ALDH1A1KDM4EHRH3GAAEPHX2 | |
| SCHEMBL15426234 | 0.83 | GAA (0.46) | ALDH1A1KDM4EHRH3GAASMN1; SMN2 | |
| SCHEMBL10193853 | 0.83 | GAA (0.46) | ALDH1A1KDM4EHRH3GAASMN1; SMN2 | |
| SCHEMBL10174124 | 0.81 | EPHX2 (0.39) | ALDH1A1KDM4EHRH3EPHX2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | ARISAPH PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | ARISAPH PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9212142-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212142-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150094303-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE | 2015-04-02 | — | — | US | disclosed |
| US-20150094303-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE | 2015-04-02 | — | — | US | disclosed |
| US-8937063-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937063-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | Arisaph Pharmaceuticals (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | Arisaph Pharmaceuticals (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450316-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450316-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077808-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077808-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094303-A1 | Niacin Mimetics, and Methods of Use Thereof | NAMPT, NADK, NAPRT | ALDH1A1 772/4885KDM4E 4511/4885HRH3 697/4885 |
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | NAMPT, NNT, NAPRT | ALDH1A1 564/4885KDM4E 3805/4885HRH3 1233/4885 |
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | NAMPT, NNT, NAPRT | ALDH1A1 564/4885KDM4E 3805/4885HRH3 1233/4885 |
| US-20120077808-A1 | Niacin Mimetics, and Methods of Use Thereof | NAMPT, NADK, NAPRT | ALDH1A1 772/4885KDM4E 4511/4885HRH3 697/4885 |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | NAMPT, NNT, NAPRT | ALDH1A1 564/4885KDM4E 3805/4885HRH3 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.